being and becoming in the world
Each summer the British Association for Psychopharmacology (BAP) has a Summer Meeting that provides accredited continuing medical education [CME] for psychiatrists and academics. It is hugely popular. A colleague of mine … Continue reading “BAPFEST”
This podcast was first aired on 23 July 2023. The second half hour of the podcast was on ‘Tackling Depression’. There were a number of contributors. In what follows I … Continue reading 5 Live Science: Tackling Depression
The Royal College of Psychiatrists describes “7 highlights” from its “sold-out”, and no doubt lucrative, International Congress 2018 which this year was held in Birmingham. Professor Hamish-McAllister’s declarations of interest … Continue reading “He delivered piercing insights”
I was recently circulated this at work and asked to share it with trainee psychiatrists. BAP is the acronym for the British Association for Psychopharmacology I would not share this … Continue reading Marketing of “education” to psychiatrists in training
I have recently posted on the promotion of Lurasidone (Latuda) in the UK. This has raised concerns for me about transparency of conflicts of interest for some of the key … Continue reading “A robust learning environment for healthcare professionals”
In my last post I considered the level of transparency provided by the British Association for Psychopharmacology (BAP) in relation to its recently published Guidelines on prescribing for depressive disorders. … Continue reading Stephen Stahl: $3,581,159 in payments from Pharma
The above Evidence-based guidelines for treating depressive disorders with antidepressants have recently been published. The British Association for Psychopharmacology are an organisation highly regarded by my profession of psychiatry. 12% of their … Continue reading British Association for Psychopharmacology Guidelines (BAP)